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Abstract
Background: The clinical prognosis of gastric cancer with peritoneal dissemination is poor because of its
chemoresistance and rich fibrosis. While several gastric cancer cell lines have been used to establish models of
peritoneal dissemination by intraperitoneal injection, most peritoneal tumors that form adopt a medullary pattern
in microscopic appearance. This histological finding for the model differs from that in the clinical situation. This
study was performed to demonstrate the contribution of human peritoneal mesothelial cells (HPMCs) to fibrotic
tumor formation and to establish a new xenograft model with high potential for peritoneal dissemination with
organ invasion and extensive fibrosis.
Methods: We established four types of xenograft model: i) intraperitoneal injection of MKN45-P cells alone (control
group), ii) injection of MKN45-P cells co-cultured with HPMCs (co-cultured group), iii) scratching the parietal
peritoneum (parietal group), and iv) scratching the visceral peritoneum (visceral group) with a cotton swab before
injection of co-cultured cells. Fibrosis, α-smooth muscle actin expression, and organ invasion by tumor cells were all
assessed by immunohistochemical examination.
Results: All mice developed abdominal swelling with peritoneal tumors and bloody ascites. Tumors of the control
and co-cultured groups were not invasive or fibrotic. Contrastingly, tumors of the scratch groups exhibited rich
stromal fibrosis and possessed increased α-smooth muscle actin (α-SMA) expression. In particular, the visceral group
showed edematous and spreading tumors invading the intestinal wall.
Conclusion: We established a model of peritoneal dissemination with organ invasion and stromal fibrosis.
Formation of peritoneal dissemination required a favorable environment for cell adhesion, invasion, and growth.
This model may be useful for analyzing the pathogenesis and treatment of peritoneal dissemination of gastric
cancer.
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Background
Gastric cancer is one of the most common malignant
diseases worldwide [1]. Peritoneal dissemination is a char-
acteristic feature of gastric cancer and is a critical factor
underlying its poor prognosis [2–4]. While clinical
outcomes for gastric cancer patients with peritoneal
dissemination have improved with advances in systemic
and/or intraperitoneal (i.p) chemotherapy, desirable
outcomes remain elusive [5–10]. Peritoneal dissemination
is characterized by cancer cell infiltration and proliferation
accompanied by extensive stromal fibrosis [11, 12]. This
results in the development of chemoresistance and
obstructive disorders such as ileus, obstructive jaundice,
and hydronephrosis. Therefore, control of organ invasion
and fibrosis is required to improve outcomes for patients
with gastric cancer.
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While several gastric cancer cell lines undergo periton-
eal dissemination following intra-peritoneal injection in
mice, almost all peritoneal tumors formed in this man-
ner adopt a medullary pattern [13–15]. We have previ-
ously reported that fibrotic tumors can be established in
a subcutaneous xenograft model using the gastric cancer
cell line MKN45 in co-culture with human peritoneal
mesothelial cells (HPMCs) [16]. However, a xenograft
model of peritoneal dissemination is required, as delivery
of therapeutic agents to the peritoneal cavity is limited
following intravenous administration because of the
peritoneal-blood barrier [17]. The establishment and
analysis of a xenograft model that exhibits similar histo-
pathological features to tumors from human gastric
cancer patients with peritoneal dissemination may facili-
tate the development of treatments for this disease.
Therefore, this study aims to establish a new xenograft
model of peritoneal dissemination with organ invasion
and fibrosis akin to the typical clinical situation.
Methods
Patients and cell lines
Surgical specimens of human omentum were obtained
from patients with no evidence of peritoneal inflamma-
tion and/or malignancy who underwent surgery in Kana-
zawa University Hospital between April and December
2013. Donors were not subjected to chemotherapy or ra-
diation treatment prior to surgery. All patients provided
written informed consent prior to participation in the
study. The study was approved by the Research Ethics
Committee of Kanazawa University (permission number
1747). HPMCs were isolated from surgical specimens of
human omentum as previously described [18]. Briefly,
small pieces of omentum were surgically resected under
sterile conditions and were incubated in pre-warmed
phosphate-buffered solution (PBS) containing 0.125%
trypsin/EDTA (Gibco/Invitrogen, USA) for 30 min at
37 °C. The suspension was centrifuged at 1500 × g for
5 min. Collected cells were cultured in RPMI-1640
medium (Gibco/Invitrogen) supplemented with 20%
heat-inactivated fetal bovine serum (FBS; Nichirei Bio-
science Inc., Japan). The cells were cultured at 37 °C in a
humidified atmosphere of 5% CO2 in air. For the follow-
ing experiments, cells were used during the second or
third passage after primary culture. HPMCs possibly
contaminated with endothelial cells or fibroblasts at the
time of harvest were not used. We used homogeneous
HPMCs from a different donor for each experiment. We
used the high-potential peritoneal dissemination cell line
MKN45-P, which was established from the MKN45 gas-
tric cancer cell line (Additional file 1: Figure S1) in our
institution as described previously [19]. Briefly, female
immunocompromised BALB/c-nu/nu mice (Charles
River Laboratories Inc. Japan) were subcutaneously
inoculated with MKN45 cells and the subcutaneous nod-
ules were removed and injected into other mice intra-
peritoneally. The cancer cells from peritoneal nodules
were injected into the abdominal cavity of other mice.
The process was continued through to a seventh gener-
ation. The resulting cell line was named MKN45-P. Cells
were maintained in RPMI-1640 medium supplemented
with 10% FBS.
Mouse xenograft model
All animal experiments were performed according to
Kanazawa University’s standard guidelines. Female im-
munocompromised BALB/c-nu/nu mice at 4–6 weeks of
age were maintained in a sterile environment. MKN45-P
cells were co-cultured with an equivalent number of
normal HPMCs for 5 days, and a total of 5 × 106 cells in
1000 μL of RPMI-1640 were then i.p. injected into nude
mice on day 0 (co-cultured group). For the control
group, 5 × 106 MKN45-P cells alone were injected (con-
trol group). The scratch method of i.p. cell inoculation
was employed. First, an abdominal incision was made
under general diethyl-ether inhalation anesthesia. For
the parietal peritoneum scratch model, the left ventral
parietal peritoneum was scratched using a cotton swab
(Fig. 1a, parietal group). For the visceral peritoneum
scratch model, the intestinal tract and mesenterium was
removed from the peritoneal cavity and scratched using
a cotton swab (Fig. 1b, visceral group). The visceral were
then returned into the peritoneal cavity and the abdom-
inal wall was closed. Next, a total of 5 × 106 cells of a
MKN45-P and HPMCs co-culture was injected i.p. and
animals were carefully monitored. After 14 days, mice
were anesthetized with diethyl-ether, sacrificed, and the
tumors and abdominal organs excised together. Tumor
specimens were then collected for immunohistochemical
examination.
Immunohistochemistry
Tumor specimens were fixed in 10% neutral buffered
formalin and embedded in paraffin. Sections were
stained with hematoxylin and eosin (H&E) and Azan
stain for assessment of fibrosis, while the expression of
α-smooth muscle actin (α-SMA; 1A4, mouse monoclo-
nal IgG, diluted 1:100; Dako Cytomation, Denmark) and
vimentin (V9, mouse monoclonal IgG, diluted 1:100;
Santa Cruz Biotechnology, Inc.) was also assessed immu-
nohistochemically. Deparaffinized sections were pre-
treated by autoclaving in 10% citric acid buffer (pH 8.0)
at 120 °C for 15 min. Following treatment with protein
block serum (Dako Cytomation, Kyoto, Japan) for
10 min and incubation with 2% skim milk for 30 min to
block non-specific reactions, sections were incubated
with primary antibody at 4 °C overnight. The Envision-
polymer solution (horseradish peroxidase, HRP, Dako
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Cytomation) was then applied for 1 h. Signals were de-
veloped in 0.02% 3,3′-diaminobenzidinetetrahydrochlor-
ide solution containing 0.1% H2O2. Sections were then
lightly counter stained with hematoxylin and examined
using a fluorescence microscope (Olympus, Tokyo,
Japan). The degree of fibrosis was calculated as a per-
centage of fibrosis within the whole section in all sam-
ples using a BZ-9000 BZII microscope (Keyence, Osaka,
Japan).
Statistical analysis
Differences among the data sets were evaluated using
one-way analysis of variance or two-sided Student’s t-
tests with the computer software package SPSS 10.0
(SPSS, Chicago, IL, USA). P values less than 0.05 indi-
cated a statistically significant difference.
Results
Macroscopic appearance
Representative images depicting the macroscopic
appearance of the tumors at Day 14 are shown in
Fig. 2. All mice developed abdominal swelling with
peritoneal tumors and bloody ascites. Tumors of both
control and co-cultured groups underwent peritoneal
dissemination, though this occurred on abdominal
organ surfaces and organ invasion was not observed
(Fig. 2a, b). Mice of the parietal group had tumors
present on the left side of the peritoneal cavity at the
scratch sites (Fig. 2c). However, dissemination nodules
did not exhibit organ invasion (Fig. 2d). Dissemination
nodules with adhesion and invasion to the intestinal
tract, block formation, and distention and edema of
the intestinal tract were observed in mice of the vis-
ceral group (Fig. 2e–g).
Microscopic appearance
Control group tumors did not exhibit fibrosis or α-SMA
and vimentin positive cells (Fig. 3a). Additionally, co-
culture group tumors showed little fibrotic change
(Fig. 3b). However, both the parietal and visceral peri-
toneum scratch model groups showed rich fibrosis and
α-SMA positive cells (Fig. 3c, d). Furthermore, visceral
group tumors invaded the intestinal tract by destroying
the serosal membrane, as serosal edges stained positively
for Azan and α-SMA (Fig. 3e). The scratch model group
also exhibited cytoplasmic expression of vimentin. The
fibrotic areas of tumors formed in conjunction with the
scratch methods were significantly larger than those of
control tumors (Fig. 4).
Fig. 1 Methods of peritoneal scratching in the xenograft model. Representative images demonstrating the procedure of scratching the peritoneum
with a cotton swab. Left panel: scratching of the parietal peritoneum. Right panel: scratching of the visceral peritoneum
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Discussion
The peritoneal dissemination xenograft model described
here mimics the clinical situation present in human
patients in several respects. For example, bloody ascites
and edematous intestines were present in the peritoneal
cavity, tumors invaded surrounding tissues such as the
digestive tract, and apparent stromal fibrosis was
present. This is the first report to describe the successful
establishment of a peritoneal dissemination model with
organ invasion and fibrosis.
Previous studies have described peritoneal dissemin-
ation xenograft models that are based on the intraperito-
neal injection of various gastric cancer cells into nude
mice [13–15]. These models develop multiple nodules
on the surfaces of abdominal organs and the peritoneal
cavity. However, these tumors did not exhibit organ
invasion or extensive stromal fibrosis. Other studies
suggest that the volume and composition of fibrous
tissue in various organs are influenced by epithelial-
mesenchymal transition (EMT), which differentiate into
an extracellular matrix-producing myofibroblast charac-
teristics [20–22]. We have previously reported that
transforming growth factor-β1 (TGF-β1) mediated acti-
vation of HPMCs induces an EMT-like process, and that
activated HPMCs function as a source of cancer-
associated fibroblasts [16, 23]. Furthermore, we have
established a subcutaneous tumor model using the gas-
tric cancer cell line MKN45 in co-culture with HPMCs
[16, 24].
This study found that intraperitoneal injection of
MKN45-P cells in co-culture with HPMCs did not result
in formation of a fibrotic tumor with organ invasion.
Fig. 2 Representative images depicting four patterns of xenograft models at day 14. Macroscopic views of peritoneal nodules (arrow head). a
control group. b co-cultured group. Peritoneal nodules are present on the surfaces of the abdominal organs, but organ invasion is not present. c,
d parietal group. Tumors are present on the scratched peritoneal portion (Dotted line). e–g visceral group. Tumors forming a block with invaded
intestinal tract and peritoneum
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Fig. 3 Histological examination of peritoneal dissemination xenograft models. Histological examination was performed by hematoxylin and eosin
(H&E) staining, Azan, α-SMA and vimentin staining in the tumor. a control group, b co-cultured group, c parietal group, d and e visceral group.
Tumors invaded to the intestine wall (Arrows). a, b, c, d original magnifications × 200. Scale bar, 50 μm. e × 40. Scale bar, 200 μm
Fig. 4 Fibrotic change in four patterns of xenograft model. Fibrotic areas were measured using Azan staining and are shown as a percentage
(fibrotic area/whole section area). Data presented are the mean ± SD. *p < 0.05 versus control group
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The MKN45-P cell line has a high potential for periton-
eal dissemination and could adhere to the mouse peri-
toneal cavity; however, injected HPMCs could not
adhere to the intact peritoneal surface. HPMCs are
classified as epithelial in the broadest sense of the term,
and serve as a protective anatomical barrier [25]. Yashiro
et al. have previously demonstrated that a layer of con-
fluent, intact mesothelial cells hindered cancer cell inva-
sion to the abdominal cavity [16]. However, the presence
of HPMCs stimulates a change in the complement of
growth factors secreted by cancer cells [12, 16]. There-
fore, the establishment of fibrotic tumors necessitates
creation of a favorable environment within the abdom-
inal cavity that enables both gastric cancer cells and
HPMCs to grow.
Clinical experience suggests that patients with free
cancer cells in the abdominal cavity do not necessarily
develop peritoneal implantation. Over 100 years ago,
Paget et al. proposed the ‘seed and soil’ theory: metasta-
sis only occurs when tumor cells (seeds) survive and
grow in a favorable organ/tissue microenvironment (soil)
[26]. This theory is central to the formation of peritoneal
dissemination in gastric cancer. For example, EMT of
HPMCs in combination with peritoneal fibrosis provides
a favorable environment for the dissemination of gastric
cancer through the naked areas of a basal membrane
[16, 19, 27]. TGF-β1 is considered a master switch for
the induction of fibrosis during EMT in multiple organs
and tissues, including the peritoneum [19–22, 28, 29]. In
a clinical scenario of peritoneal dissemination, HPMCs
would expose a basal membrane as an anchorage point
by adopting a spindle-shape morphology under the in-
fluence of cancer cell-derived cytokines, including TGF-
β1 [16]. Integrin molecules expressed on cancer cells
play a crucial role in initial adhesion to the basal mem-
brane [30, 31]. Later, cancer cell-derived matrix metallo-
proteinases degrade the basal membrane, facilitating
cancer cell invasion of the deeper tissue [32]. Therefore,
scratching of the mouse peritoneum likely facilitated for-
mation of fibrotic and invasive tumors because the basal
membrane was exposed as an anchorage site for cancer
cells and HPMCs.
Peritoneal dissemination is the most frequent pattern
of recurrence after curative resection of gastric cancer.
Previous studies reported that peritoneal recurrence was
evident in 43–57% of gastric cancer patients, while
hematogenous recurrence occurred in 26–54%, and
lymph node recurrence and local recurrence developed
in 17–25.8% of individuals [33–36]. Our xenograft
model mimics the peritoneal defect formed by the peel-
ing of mesothelial cells during gastrectomy and lymph
node dissection. In other words, surgical procedures
themselves may provide a favorable environment for
peritoneal dissemination. Therefore, future investigations
should focus on the pathogenesis of peritoneal dissemin-
ation as well as novel treatment strategies for the pre-
vention of peritoneal fibrosis.
Conclusion
We have established a murine model of peritoneal dissem-
ination that mimics the clinical findings of fibrosis and
invasion in human gastric cancer patients. This model
involves scratching of the peritoneal surface and injection
of co-cultured gastric cancer cells and HPMCs. This
model may be useful for evaluating strategies for treat-
ment of peritoneal dissemination of gastric cancer.
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